Skip to content


  • Research
  • Open Access

A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation

  • 1, 2,
  • 2,
  • 1, 2,
  • 1, 2,
  • 2,
  • 2,
  • 2,
  • 3,
  • 3,
  • 4,
  • 5,
  • 1,
  • 2Email author and
  • 6
Genetic Vaccines and Therapy20108:7

  • Received: 13 August 2010
  • Accepted: 1 November 2010
  • Published:



Immunization of mice with tumor homogenate after combined treatment with cyclophosphamide (CP) and double-stranded DNA (dsDNA) preparation is effective at inhibition of growth of tumor challenged after the treatment. It was assumed that this inhibition might be due to activation of the antigen-presenting cells. The purpose was to develop improved antitumor strategy using mice. We studied the combined action of cytostatics doxorubicin (Dox) plus CP with subsequent dsDNA preparation on tumor growth.


Three-month old CBA/Lac mice were used in the experiments. Mice were injected with CP and human dsDNA preparation. The percentage of mature dendritic cells (DCs) was estimated by staining of mononuclear cells isolated from spleen and bone marrow 3, 6, and 9 days later with monoclonal antibodies CD34, CD80, and CD86. In the next set of experiments, mice were given intramuscularly injections of 1-3 × 105 tumor cells. Four days later, they were injected intravenously with 6-6.7 mg/kg Dox and intraperitoneally with 100-200 mg/kg CP; 200 mkg human DNA was injected intraperitoneally after CP administration. Differences in tumor size between groups were analyzed for statistical significance by Student's t-test. The MTT-test was done to determine the cytotoxic index of mouse leucocytes from treated groups.


The conducted experiments showed that combined treatment with CP and dsDNA preparation produce an increase in the total amount of mature DCs in vivo. Treatment of tumor bearers with preparation of fragmented dsDNA on the background of pretreatment with Dox plus CP demonstrated a strong suppression of tumor growth in two models. RLS, a weakly immunogenic, resistant to alkalyting cytostatics tumor, grew 3.4-fold slower when compared with the control (p < 0.001). In experiment with Krebs-2 tumor, only 2 of the 10 mice in the Dox+CP+DNA group had a palpable tumor on day 16. The cytotoxic index of leucocytes was 86.5% in the Dox+CP+DNA group, but it was 0% in the Dox+CP group.


Thus, the set of experiments we performed showed that exogenous dsDNA, when administered on the background of pretreatment with Dox plus CP, has an antitumor effect possibly due to DC activation.


  • Antitumor Immune Response
  • Tumor Homogenate
  • Protein Calreticulin
  • dsDNA Preparation
  • Allogenic Mixed Lymphocyte Culture


The most effective antitumor treatment is currently achieved by chemotherapeutic agents that abrogate tumor cells [1]. Despite this, chemotherapy is virtually without influence on life expectancy of patients with certain cancers. With this in mind, novel strategies for treating malignancies are being developed in experiments and applied in clinical setting. These are targeted towards potentiation of immune mechanisms of antitumor defense [2, 3]. The conventional vaccines are utilized, also those based on the pathogen-associated molecular patterns (PAMPs) of bacteria, including endo/exotoxins of bacterial origin, and CpG DNA preparations [412].

Dendritic cells (DCs), which are capable of activating T-lymphocytes, including naive T-cells, have an important role in triggering and development of the adaptive immunity [9, 13, 14]. Mature DCs that express MHC antigens of class I and class II, also the various costimulatory molecules CD40, CD54, CD80, and CD86 are capable of only presenting foreign antigens within the MHC complex [1521].

Search of novel inducers of antitumor immunity has been intense over the past years. It has been revealed that mammalian double-stranded DNA (dsDNA) induces both humoral and adaptive immune responses [15, 22, 23]. This induction is provided by the action of dsDNA preparations primarily on professional antigen-presenting cells. This process enfolds via the TLR-independent pathway and is mainly due to activation of TANK-binding kinase-1, TBK1 [2227]. As a result of internalization of exogenous DNA, DCs up-regulate expression and secretion of type I interferon-beta (INF-β) [22, 25]. In addition, dsDNA induces complete DC maturation, by stimulating expression of cofactor molecules on cell wall needed for development of the adaptive immunity [15].

Cyclophosphamide (CP) is a drug widely applied in the clinic to treat cancers. The effect is predominantly based on direct cytotoxic action on tumor cells resulting in their lysis. CP has an influence on CD4+CD25+FoxP3 regulatory T cells. Regulatory T cells accumulate predominantly in the tumor microenvironment and lymphoid organs [28] where they suppress activation and proliferation of the other immune cells [2832]. When administered at moderate doses, CP not only induces a reduction in numbers of regulatory T cells [3335], also diminishes their functionality [32, 34], thereby allowing to reduce the intensity of the immunosuppressive background in tumor microenvironment and to activate the antitumor immune response [31, 32, 35]. The effect of CP on various DC subsets was manifest as enhancement of antitumor immunity [3638].

It has been amply demonstrated that under the combined effect of CP and dsDNA preparation (CpG DNA, for example), the immune system is stimulated and tumor growth is suppressed [for reference, see 9]. The therapeutic effect is synergic in that cytostatic preferentially decreases the amount of regulatory T cells in the tumor microenvironment and/or directly kills tumor cells, while dsDNA preparation stimulate maturation and activity of cells of the adaptive immunity [9, 39].

There are chemotherapeutic agents capable of potentiating immunogenicity of tumor cells directly at the level of the organism. Doxorubicin (Dox), idarubucin, and mitoxanthrone, cytostatics of the antracycline series, are of this kind. A relevant observation was that induction of exposure of the protein calreticulin on cell surface of dying cells is required for activation of the antitumor immune system [40, 41]. Calreticulin is a calcium-binding lectin chaperone, mainly represented on endoplasmic membrane. Its exposure on cell surface of dying tumor cells acts as an "eat me" signal for removal by neighboring phagocytic cells [40, 42] and facilitates thereby their almost instantaneous capture [41]. The combination of Dox with cytostatic drugs (CP plus paclitaxel) and whole-cell vaccines was highly effective in enhancing antitumor response in transgenic mice [43].

Here, we demonstrate that human exogenous dsDNA preparation induces maturation of mouse spleen and bone marrow DCs in vivo. To evaluate the efficacy of vaccination with human dsDNA preparation, we chose a strategy whereby mice were treated with preparation of fragmented dsDNA on the background of pretreatment with Dox plus CP. This strategy provided the presence of tumor antigens thanks to the in vivo abrogation of tumor by the combined action of cytostatics. The subsequently injected dsDNA preparation induced effective DC maturation. This strategy demonstrated a considerable delay in tumor growth. Cytotoxic test provided evidence indicating that in the blood there appeared a cell population with high, up to 86.5%, cytotoxic activity against cells of the challenged tumor.


Laboratory animals and tumor models

Three-month old CBA/Lac mice (henceforth designated as CBA) that were bred at the animal facility of the Institute of Cytology and Genetics (IC&G), the Siberian Branch of the Russian Academy of Sciences, were used in experiments. Mice in groups of 10 were housed in plastic cages in a well-illuminated room. They had free access to food and water. All experiments were performed in accordance with protocols approved by the Animal Care and Use Committee of the IC&G.

Krebs 2 ascitic carcinoma is a strain-nonspecific tumor derived from epithelial cells; all inbred mouse strains can be challenged with Krebs 2 tumor cells. When challenged subcutaneously (s.c.) or intramuscularly (i.m.), it grows as solid nodes. It is weakly immunogenic for mice of all strains. It does not give rise to metastases [44].

Lymphosarcoma LS is strain-specific to CBA mice; it was induced in them by nitrosomethylurea, passages in ascitic form. When challenged i.m., it grows as solid nodes. It develops in 100% of challenged mice, does not regress spontaneously. It is subjected to apoptosis under the effect of alkylating antitumor agents. It metastasizes to liver, kidneys, lungs. Lymphosarcoma RLS-40 is a version of LS tumor. It is resistant to alkylating compounds [45, 46].

Mice were injected i.m. into the right hind limb with tumor cells at a dose of 1-3 × 105 cells/mouse. The tumors were allowed to grow to solid nodes. As soon as tumor became palpable, about 7 days after challenge, it size was measured with calipers every 1-2 days. Tumor size was calculated by multiplying the three perpendicular diameters. Differences in tumor size between groups were analyzed for statistical significance by Student's t-test.

DNA preparation

Human DNA preparation was isolated from the placentas of healthy women using a phenol-free method. It was fragmented in an ultrasonic disintegrator at a frequency of 22 kHz to obtain a mixture of DNA fragments with a size 200-6,000 bp. The human DNA was a pharmacopeian preparation "Panagen" (Registration certificate Medical Drugs of Russia No. 004429/08 of 09.06.2008). This preparation does not contain steroid hormones and RNA. It gives negative PCR results for hepatitis B virus DNA, hepatitis C virus RNA, HIV DNA, HIV RNA. The DNA preparation does not contain histones and polysaccharides; it is also endotoxin-free.

Estimation of DC maturity in vivo

Mice were injected with CP (Veropharm, Russia) at 200 mg/kg and 200 mkg of human dsDNA preparation 1 day (on the day of CP injection), 3, 4, and 5 days after CP treatment. Three, 6, and 9 days later, the fraction of mononuclear cells (MNCs) was isolated from spleen and bone marrow. MNCs were isolated also from untreated mice. Every group consisted of 4-6 mice. The experiment was repeated twice.

Mice were anesthetized and sacrificed by cervical dislocation. Femurs and tibias were removed and bone marrow cells were flushed from them by RPMI-1640 (Sigma-Aldrich) medium. Washed bone marrow cells (DC precursors) were suspended in RPMI-1640. Spleen contents were scraped out with pincers into Petri dishes and resuspended in PBS. The obtained cell suspension was applied onto 3 ml ficoll 400 (Farmaceg) - urografin (Schering) gradient, centrifuged (5810R, Eppendorf) at 1,500 rpm for 30 min. MNCs were collected, washed and precipitated. Cell residue was suspended in RPMI-1640, the number of cells was counted and diluted to 2 × 105 in 200 μl of medium.

The percentage of mature spleen and bone marrow DCs was estimated by staining with monoclonal antibodies CD34-PerCP, CD80-FITC, and CD86-PE (Santa Cruz). Cells were analyzed on a flow cytofluorometer BD FACSAria (BD Biosciences). Additional file 1 is a dot plot figure of the event gating for CP+DNA group.

Statistics was based on estimates of the number of mature DCs relative to the total number of isolated MNCs.

Schedule for treatment with exogenous dsDNA preparation after administration of cytostatics Dox plus CP

CBA mice were given an i.m. challenge with 105 RLS-40 tumor cells. Four days later, they were injected intravenously (i.v.) with 6.7 mg/kg Dox (Veropharm, Russia) and i.p. with 100 mg/kg CP; 200 mkg human DNA was injected i.p. after 30 min, then 2 and 3 days after CP administration. Mice were assigned to three groups (n = 10) according to treatment schedule: 1) challenged tumor + PBS injections (control); 2) Dox + CP; 3) Dox + CP + DNA.

CBA mice were given 3 × 105 Krebs-2 tumor cells injected i.m.. Four days later, they were administered i.v. 6 mg/kg Dox and i.p. 200 mg/kg CP; 200 mkg human DNA was administered i.p. 30 min after CP, also 2, 3, and 5 days after it. Assignment of mice to groups, with 10 in each, was as follows: 1) challenged tumor + PBS injections (control); 2) Dox + CP; 3) DNA; 4) Dox + CP + DNA. The experiment was done in triplicate.

The dosages of Dox and CP were the conventionally used for chemotherapy in the clinic, 100-200 mg/kg for CP and 6-7 mg/kg for Dox. The DNA preparation was used at 200 mkg/mouse/injection. This amount has been defined in experiments [39].

MTT test

Mice of all the 4 groups and one untreated mouse were sacrificed by decapitation on day 16 after tumor Krebs-2 challenge. Blood (200-500 μl) was drawn into tubes containing 800 μl PBS with 50 mM EDTA. Blood cells were precipitated by centrifugation (5810R, Eppendorf) at 1,500 rpm for 5 min at room temperature; erythrocytes from cell residue were lysed with 0.15 M ammonium chloride.

In in vitro cytotoxicity study, Krebs-2 cells were plated in 96-well plates (3 × 104 cells/well), and mouse leucocytes were added at a 1:1 ratio. Cells were incubated in RPMI-1640 medium supplemented with gentamycin sulfate (100 mkg/ml) and maintained at 37°C for 18 h in 5% CO2 atmosphere. After incubation, MTT (Sigma) was added to a final concentration of 0.5 mg/ml and cells were cultured for additional 3 h. Cells were centrifuged (5810R, Eppendorf) at 4,000 rpm for 10 min. Medium was collected, precipitated blue formasan crystals were dissolved in 100 μl DMSO. Optical density was determined on a Multiscan RC at 570 nm, background was subtracted at 620 nm. Measurements were done for three samples. The MTT-test was repeated twice for different experiments.

The standard formula was applied to calculate the percentage of dead cells:
( % ) = [ 1 ( D e + t D e ) / D t ] × 1 00 ,

De+t, the optical density value in wells with cells from mice of the treated groups incubated with tumor cells;

De, the optical density value in wells with effectors (leucocytes);

Dt, the optical density value in wells with targets (tumor cells).

The cytotoxic index (CI) was expressed as the difference between the percentage of dead cells in the treated groups and the untreated mouse.


Our previous study has demonstrated that a preparation of human fragmented dsDNA stimulated maturation of mouse DCs in culture [47]. The salient finding was that the dsDNA preparation was just as effective at induction of DC maturation as the standard inducer TNF-α. The obtained mature DCs loaded with antigen during maturation were used in the comparative test. A marked antitumor effect was observed after vaccination with DCs irrespective of the type of maturation inducer [47].

Previous experimental sets with Krebs-2 tumor demonstrated that immunization of mice with tumor homogenate after combined treatment with CP and dsDNA preparation is effective at inhibition of growth of tumor challenged after the treatment (Figure 1) [39]. Proceeding on reported observations [14, 39, 47], we assumed that this inhibition may be due to the inducer effect of dsDNA on DC maturation in vivo that causes effective presentation of antigens of tumor lysate and activates antitumor mechanisms of the adaptive immunity.
Figure 1
Figure 1

Time course of Krebs-2 tumor growth in mice (mean ± SEM). Time course of Krebs-2 tumor growth in mice (mean ± SEM). Mice received 200 mg/kg CP and human DNA at a total dose 4.5-6 mg. After this treatment, one group of mice was pre-immunized with Krebs-2 tumor antigens by a s.c. injection of 20 × 106 repeatedly thawed-frozen tumor cells. The control group was injected with saline. Every group consisted of 10 mice. 106 Krebs-2 tumor cells were challenged i.m. after the treatment. Immunization enhanced the suppressive effect on tumor growth [31].

The results provided evidence indicating that the described antitumor activity was not related to natural killer cells [39]. This appeared plausible, because, to our knowledge, NK-cells neither displayed nor enhanced antigen-specific cytotoxicity associated with tumor homogenate immunization [48, 49].

Effect of dsDNA preparation on maturation of spleen and bone marrow DCs in vivo

To obtain assurance that dsDNA has an inducer effect on DCs in vivo, a set of experiments was undertaken. Mice were treated with CP 200 mg/kg followed by 200 mkg human dsDNA preparation administration 1, 3, 4, and 5 days after CP injection. The number of mature CD34-CD80+CD86+ DCs among spleen and bone marrow cells was estimated 3, 6, and 9 days after CP had been injected (Figure 2).
Figure 2
Figure 2

Time course of maturation of mouse DCs from spleen (A) and bone marrow (B) after treatment with CP and dsDNA preparation (mean ± SEM). Time course of maturation of mouse DCs from spleen (A) and bone marrow (B) after treatment with CP and dsDNA preparation (mean ± SEM). 0 represents the number of mature DCs in untreated mice. Mice were injected with CP 200 mg/kg and 200 mkg of human dsDNA preparation 1 day (on the day of CP injection), 3, 4, and 5 days after CP treatment. Three, 6, and 9 days later, the fraction of MNCs was isolated from spleen and bone marrow. Every group consisted of 4-6 mice. The experiment was repeated twice.

The peak of spleen DC maturation was 3 days after combined DNA+CP treatment. This peak was followed by a decrease in the number of mature DCs presumably due to migration of cells to lymph nodes and other sites of their specific localization. Mouse groups treated with an agent alone, CP or dsDNA preparation, showed no marked increase in the number of mature DCs.

The peak of bone marrow DC maturation in the DNA and DNA+CP groups was also on day 3. In the case of DNA+CP treatment, the interval during which DCs retained mature phenotype and were able to effectively present antigen was longer, several days. DNA alone caused a transient rise in level of mature DCs. In the CP group, the number of mature DCs in bone marrow reached the maximum by day 6 only, thereafter it decreased to the initial level.

Thus, the conducted experiments showed that combined treatment with CP and dsDNA preparation produces an increase in the total amount of mature DCs. This was associated with an increase in the time during which mature DCs persisted at high levels.

Effect of inhibition of tumor growth induced by Dox+CP+DNA treatment

Our previous studies have demonstrated that the CP+DNA combination was statistically superior to each treatment modality alone [39, 50]. From comparisons of schedules, the standard with additional immunization with tumor homogenate, it followed that the presence of specific antigens further enhanced the suppression effect on tumor growth. There were reasons for suggesting that the integration of cytostatics with dsDNA preparation may be a treatment modality for enhancing regression of established tumors.

According to the data in the literature a combination of cytostatics is superior to each modality alone [51, 52]. Two-three potent drugs are usually combined in the clinic. In the current study, we did not strive to control the effectiveness of a drug as monotherapeutic agent. We were rather interested in the antitumor action of DNA preparation when used in combination with cytostatics Dox and CP.

Proceeding on the combined cytotoxic action of Dox and CP, also on the course of changes in DC maturation in vivo, a set of experiments was designed. The idea was to superimpose the effects of released tumor antigens and of their capture by DCs. Mice bearing established tumors were treated on day 4 with Dox and CP, thereafter they were injected with human dsDNA preparation. As known [41, 53], Dox provides the exposure of the cell surface endoplasmic protein calreticulin that acts as an "eat me" signal and mediates the phagocytosis of tumor cells by DCs. CP abrogates tumor cells, thereby increasing the amount of free tumor antigens that, thanks to the "eat me" signal, are uptaken promptly, and presented by DCs. The induction of DC maturation is the necessary condition for antigen presentation on the surface of DCs. In the following experiments, we chose dsDNA preparation as a maturation stimulus.

Using this schedule, a strong suppression of tumor growth was observed in two murine models. The size of RLS, a weakly immunogenic, resistant to alkalyting cytostatics tumor, on day 14 was 3.4-fold smaller (p < 0.001) in the Dox+CP+DNA group compared with the control (Figure 3). The difference in RLS size on day 14 between the groups Dox+CP and Dox+CP+DNA was 1.5-fold (p < 0.1).
Figure 3
Figure 3

Time course of RLS tumor growth in mice that received combined treatment with Dox, CP, and dsDNA preparation (mean ± SE). Time course of RLS tumor growth in mice that received combined treatment with Dox, CP, and dsDNA preparation (mean ± SE). Mice were given i.m. injections of 105 RLS-40 tumor cells. Four days later, they were injected i.v. with 6.7 mg/kg Dox and i.p. with 100 mg/kg CP; 200 mkg human DNA was injected i.p. after 30 min, then 2 and 3 days after CP administration. The control group was injected with PBS. Every group consisted of 10 mice.

Krebs-2 tumor growth was effectively suppressed as compared to the control in both Dox+CP and Dox+CP+DNA groups (p < 0.001) (Figure 4). A tumor burden was of measurable size 16 days after treatment in 9 of the 10 mice in the Dox+CP group, but only in 2 of the 10 mice tumor was palpable on day 16 in Dox+CP+DNA group. There was a 14-fold significant difference (p < 0.005) in tumor size on day 14 between the Dox+CP and Dox+CP+DNA groups. Injection of dsDNA preparation alone slightly suppressed Krebs-2 tumor growth, the difference from the control being significant, however (p < 0.05).
Figure 4
Figure 4

Time course of Krebs-2 tumor growth in mice treated with Dox, CP, and dsDNA preparation (mean ± SE). Time course of Krebs-2 tumor growth in mice treated with Dox, CP, and dsDNA preparation (mean ± SE). Mice were given 3 × 105Krebs-2 tumor cells injected i.m.. Four days later, they were administered i.v. 6 mg/kg Dox and i.p. 200 mg/kg CP; 200 mkg human DNA was administered i.p. 30 min after CP, also 2, 3, and 5 days after it. The control group was injected with PBS. Every group consisted of 10 mice. The experiment was done in triplicate.

The schedule for DNA preparation administration differed slightly from the one we applied to estimate the efficacy of DC maturation in vivo. DNA was injected at the time when the number of mature DCs was maximum.

We used CP at high doses since evaluation of therapeutic combined action of CP and dsDNA did not demonstrate enhancement of antitumor effect with low-dose CP (data not shown).

Estimation of cytotoxic activity of blood cells in mice with Krebs-2 tumor after combined treatment with Dox+CP+dsDNA preparation

The experimental results provided evidence for activation of the antitumor immune response in vivo. Supporting data of the MTT test were required. For this purpose, treated mice bearers of Krebs-2 tumor were sacrificed 16 days after treatment. All the mouse groups could be monitored at the same time, on day 16 for the presence of cytotoxic cells. This became feasible because tumors reached the size that led to lethal development in the control group. Tumor size in the treated groups attained a statistically significant difference from the control by this time.

Peripheral blood was monitored for the appearance of cells showing antitumor cytotoxic activity. Krebs-2 cells derived from ascitic version of tumor served as targets (Table 1).
Table 1

Cytotoxic activity of leucocytes in MTT test.



Dead cells, %


Tumor cells (targets)



Leucocytes (effectors)



Untreated mouse




Control (tumor only)
















The cytotoxic index (CI) was expressed as the percentage of dead cells relative to their number in an untreated mouse. It was 86.5% in the Dox+CP+DNA group, consistent with the time course of tumor growth (Figure 4). It was 0% in the Dox+CP group, although there was a considerable suppression of tumor growth. This may be attributed to the direct cytostatic effect on tumor growth of the kind that does not enhance cytotoxic activity of circulating leucocytes. Such was the case, because there was no DNA stimulus for DC maturation and ultimate development of antigen-specific immune responses. dsDNA preparation itself raised cell cytotoxic activity to 44.2%, but tumor growth was suppressed just slightly.


Tumors have unique properties allowing them to elude immune defense. To begin with, they are genetically flexible owing to the incessantly activated repair-recombination system of tumor cells [32]. Second, tumor tissue takes advantage of the properties of regulatory T lymphocytes. Third, a tumor is, as a rule, weakly immunogenic and this makes the more difficult for the immune system to reveal malignized cells and to eradicate them. Modulation or elimination of these three properties of tumors would create conditions favorable for the immune system to eliminate neotransformed cells [1, 13, 54, 55].

The current increasing trend is to affect tumor tissue by using in a defined sequence two modalities, a chemotherapeutic (a cytostatic, most commonly CP) followed by an immunotherapeutic [21, 5658]. This strategy is fully consistent with the idea how tumor tissue may be affected. To recapitulate, CP directly attacks tumor cells, it also causes a decrease in the numbers of regulatory T cells and reduces their functionality [21, 32, 34, 35, 58, 59], thereby improves the efficacy of immune-based therapies directed at stimulation/enhancement of antitumor immune responses.

Recent studies on the chemotherapeutic effects of antracyclines have established that Dox, for example, transposes calreticulin to the cell surface. This protein may play the role of surveillance "eat me" signal and mediate the phagocytosis of tumor cells by DCs. As a result, tumor immunogenicity is enhanced [41, 53].

Cytostatics (CP and Dox) in combination with immunotherapeutics (DNA activators) allow to develop improved antitumor strategy. CP directly injures tumor cells, concomitantly switches regulatory T cells off. Dox also abrogates tumor and renders tumor cell debris immunogenic. The DNA activated immune system kills the remaining neotransformed cells at the time when the regulatory T-lymphocytes are inactive and tumor is defenseless.

In the current experiments, we relied on the ability of dsDNA to induce complete DC maturation ex vivo reasonably expecting that this would augment their stimulatory activity in an allogenic mixed lymphocyte culture [14, 22, 47]. It was a reasonable assumption that dsDNA would manifest its stimulatory action on DCs at the level of the whole organism. The suggestion that antitumor dsDNA activity [39, 50, 60] is due to precisely endogenous DC activation and development of the adaptive immune response lent credibility to our line of reasoning.

We determined the extent to which spleen and bone marrow derived DCs were mature and followed the time course of changes in their quantitative accumulation after different treatments. Given the results, a schedule for combined Dox plus CP, which form apoptotic/necrotic debris, plus dsDNA preparation was developed. Strongest suppression of tumor growth was achieved with this schedule and an optimal sequence of administration of each modality. Its effectiveness was confirmed by the MTT test estimates. The suppression effect on tumor growth was, indeed, due to both damaging action of cytostatics and formation of a pool of cytotoxic cells. Importantly, challenged tumors virtually stopped growing when chemotherapeutic agents were combined with dsDNA preparation.


Thus, the set of experiments we performed showed that exogenous dsDNA, when administered on the background of pretreatment with Dox plus CP, has an antitumor effect possibly due to DC activation. The effect may be also explained by DC-mediated activation of cytotoxic T-lymphocytes [37, 38]. Crucial here are the mature phenotype of DCs, i.e. their antigen-presenting ability, and the real presence of tumor antigens achieved by combined treatment with Dox and CP.

The described approach to therapy of cancers appears promising. Injections of dsDNA preparation may be well integrated into classical schedules of chemotherapy.



The work was funded by federal target program "Scientific and educational manpower of innovative Russia (2009-2013)" No. 2009-1.1-203-020-010_0091 and LLC Panagen. The authors are grateful to Anna Fadeeva for translating the manuscript from Russian to English.

The authors express their gratitude to Vladimir Rogachev for production and purification of the preparation "Panagen" substance.

Authors’ Affiliations

Novosibirsk State University, Novosibirsk, Russia
Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russia
Institute of Clinical Immunology, Siberian Branch, Russian Academy of Medical Sciences, Novosibirsk, Russia
Municipal Hospital, Oncology Department, Novosibirsk, Russia
Regional Oncologic Dispensary, Irkutsk, Russia
LLC Panagen, Gorno-Altaisk, Russia


  1. Granov AM, Molchanov OE: Carcinogenesis and tumor immunobiology. Basic and clinical aspects. Vopr Onkol. 2008, 54: 401-409. In RussianPubMedGoogle Scholar
  2. Pulendran B: Variegation of the immune response with dendritic cells and pathogen recognition receptors. J Immunol. 2005, 174: 2457-2465.View ArticlePubMedGoogle Scholar
  3. Olishevsky SV, Kozak VV, Yanish YuV, Rybalko SL, Shliakhovenko VA: Immunostimulatory CpG DNA: prospects for clinical use in oncology. Oncologia. 2006, 8: 209-217. In RussianGoogle Scholar
  4. Baldueva IA: Antitumor vaccines. Applied oncology. 2003, 4: 157-166. In RussianGoogle Scholar
  5. Ishii KJ, Kawakami K, Gursel I, Conover J, Joshi BH, Klinman DM, Puri RK: Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin. Clin Cancer Res. 2003, 9: 6516-6522.PubMedGoogle Scholar
  6. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR: CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res. 2003, 9: 3105-3114.PubMedGoogle Scholar
  7. Klinman DM: Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004, 4: 249-258. 10.1038/nri1329.View ArticlePubMedGoogle Scholar
  8. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006, 5: 471-484. 10.1038/nrd2059.View ArticlePubMedGoogle Scholar
  9. Krieg AM: Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007, 117: 1184-1194. 10.1172/JCI31414.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Lee MS, Kim YJ: Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem. 2007, 76: 447-480. 10.1146/annurev.biochem.76.060605.122847.View ArticlePubMedGoogle Scholar
  11. Medzhitov R: Recognition of microorganisms and activation of the immune response. Nature. 2007, 449: 819-826. 10.1038/nature06246.View ArticlePubMedGoogle Scholar
  12. Rakoff-Naum S, Medzhitov R: Role of Toll-like receptors in tissue repair and carcinogenesis. Biokhimia. 2008, 73: 690-698. In RussianGoogle Scholar
  13. Berejnoy AE, Gnuchev NV, Georgiev GP, Kozlov AM, Larin SS: Molecular mechanisms of interaction between tumor and the immune system. Vopr Onkol. 2008, 54: 669-683. In RussianGoogle Scholar
  14. Alyamkina EA, Dolgova EV, Likhacheva AS, Rogachev VA, Sebeleva TE, Nikolin VP, Popova NA, Kiseleva EV, Orishchenko KE, Sakhno LV, Gel'fgat EL, Ostanin AA, Chernykh ER, Zagrebelniy SN, Bogachev SS, Shurdov MA: Exogenous allogenic fragmented double-stranded DNA is internalized into human dendritic cells and enhances their allostimulatory activity. Cell Immunol. 2010, 262: 120-126. 10.1016/j.cellimm.2010.01.005.View ArticlePubMedGoogle Scholar
  15. Ishii KJ, Suzuki K, Coban C, Takeshita F, Itoh Y, Matoba H, Kohn LD, Klinman DM: Genomic DNA released by dying cells induces the maturation of APCs. J Immunol. 2001, 167: 2602-2607.View ArticlePubMedGoogle Scholar
  16. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996, 184: 465-472. 10.1084/jem.184.2.465.View ArticlePubMedGoogle Scholar
  17. Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F, MacDonald HR: In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest. 2003, 111: 1673-1681.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Zhang S, Li WF, Zhang HJ, Wang Q: Antitumor reactivity of splenocytes primed in vivo with dendritic-cell-based vaccine and secondarily activated with a cocktail of cytokines in vitro. Exp Oncol. 2004, 26: 243-245.PubMedGoogle Scholar
  19. Dullaers M, Van Meirvenne S, Heirman C, Straetman L, Bonehill A, Aerts JL, Thielemans K, Breckpot K: Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 2006, 13: 630-640. 10.1038/ ArticlePubMedGoogle Scholar
  20. Kim JH, Majumder N, Lin H, Watkins S, Falo LD, You Z: Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther. 2005, 16: 1255-1266. 10.1089/hum.2005.16.1255.View ArticlePubMedGoogle Scholar
  21. Taieb J, Chaput N, Schartz N, Roux S, Novault S, Menard C, Ghiringhelli F, Terme M, Carpentier AF, Darrasse-Jeze G, Lemonnier F, Zitvogel L: Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol. 2006, 176: 2722-2729.View ArticlePubMedGoogle Scholar
  22. Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ: Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin. 2008, 4: 453-456.View ArticlePubMedGoogle Scholar
  23. Martin DA, Elkon KB: Intracellular mammalian DNA stimulates myeloid dendritic cells to produce type I interferons predominantly through a toll-like receptor 9-independent pathway. Arthritis Rheum. 2006, 54: 951-962. 10.1002/art.21677.View ArticlePubMedGoogle Scholar
  24. Ishii KJ, Akira S: Innate immune recognition of, and regulation by, DNA. Trends Immunol. 2006, 27: 525-532. 10.1016/ ArticlePubMedGoogle Scholar
  25. Shirota H, Ishii KJ, Takakuwa H, Klinman DM: Contribution of interferon-beta to the immune activation induced by double-stranded DNA. Immunology. 2006, 118: 302-310. 10.1111/j.1365-2567.2006.02367.x.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, Uematsu S, Takeuchi O, Takeshita F, Coban C, Akira S: TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature. 2008, 451: 725-729. 10.1038/nature06537.View ArticlePubMedGoogle Scholar
  27. Takeshita F, Ishii KJ: Intracellular DNA sensors in immunity. Curr Opin Immunol. 2008, 20: 383-388. 10.1016/j.coi.2008.05.009.View ArticlePubMedGoogle Scholar
  28. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004, 10: 942-949. 10.1038/nm1093.View ArticlePubMedGoogle Scholar
  29. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999, 59: 3128-3133.PubMedGoogle Scholar
  30. Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity by removing. J Immunol. 1999, 163: 5211-5218.PubMedGoogle Scholar
  31. Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ: CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol. 2003, 171: 5931-5939.View ArticlePubMedGoogle Scholar
  32. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005, 105: 2862-2868. 10.1182/blood-2004-06-2410.View ArticlePubMedGoogle Scholar
  33. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM: Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med. 2005, 201: 1591-1602. 10.1084/jem.20042167.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Ikezawa Y, Nakazawa M, Tamura C, Takahashi K, Minami M, Ikezawa Z: Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. J Dermatol Sci. 2005, 39: 105-112. 10.1016/j.jdermsci.2005.02.002.View ArticlePubMedGoogle Scholar
  35. Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, Nagayama Y, Eguchi K: Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep. 2006, 16: 141-146.PubMedGoogle Scholar
  36. Darrasse-Jeze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, Yao KH, Masilamani RF, Dustin ML, Rudensky A, Liu K, Nussenzweig MC: Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med. 2009, 206: 1853-1862. 10.1084/jem.20090746.PubMed CentralView ArticlePubMedGoogle Scholar
  37. Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN: Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 2010, 115: 4384-4392. 10.1182/blood-2009-11-251231.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Salem ML, El-Naggar SA, Cole DJ: Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol. 2010, 261: 134-143. 10.1016/j.cellimm.2009.11.011.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Alyamkina EA, Dolgova EV, Likhacheva AS, Rogachev VA, Sebeleva TE, Nikolin VP, Popova NA, Orishchenko KE, Strunkin DN, Chernykh ER, Zagrebelniy SN, Bogachev SS, Shurdov MA: Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice. Genet Vaccines Ther. 2009, 7: 12-10.1186/1479-0556-7-12.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM: Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005, 123: 321-334. 10.1016/j.cell.2005.08.032.View ArticlePubMedGoogle Scholar
  41. Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G: Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res. 2007, 67: 7941-7944. 10.1158/0008-5472.CAN-07-1622.View ArticlePubMedGoogle Scholar
  42. Henson PM, Hume DA: Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 2006, 27: 244-250. 10.1016/ ArticlePubMedGoogle Scholar
  43. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001, 61: 3689-3697.PubMedGoogle Scholar
  44. Yushok WD, Mallalieu LJ, Batt WG: Properties of Krebs 2 ascites carcinoma cells: Weight, size, specific gravity, and protein content. Journal of the Franklin Institute. 1956, 262: 507-509. 10.1016/0016-0032(56)90688-3.View ArticleGoogle Scholar
  45. Poteryaeva ON, Falameeva OV, Zhanaeva SY, Svechnikova IG, Korolenko TA, Kaledin VI: Role of cystatin C and cysteine proteinases in the development of mouse LS-lymphosarcoma. Bull Exp Biol Med. 2001, 132: 675-677. 10.1023/A:1012584429734.View ArticlePubMedGoogle Scholar
  46. Nikolin VP, Kaledin VI, Baimak TIu, Galiamova MR, Popova NA, Voitsitskii VE: Apoptosis-inducing and anti-tumor effect of cyclophosphamide, cisplatin and adriamycin used separately or combined in murine lymphosarcoma LS. Vopr Onkol. 2002, 48: 211-215. In RussianPubMedGoogle Scholar
  47. Alyamkina EA, Leplina OY, Sakhno LV, Chernykh ER, Ostanin AA, Efremov YR, Shilov AG, Proskurina AS, Orishchenko KE, Dolgova EV, Rogachev VA, Nikolin VP, Popova NA, Zagrebelniy SN, Bogachev SS, Shurdov MA: Effect of double-stranded DNA on maturation of dendritic cells in vitro. Cell Immunol. 2010, PMID: 20863487Google Scholar
  48. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA. 1996, 93: 12445-12450. 10.1073/pnas.93.22.12445.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC: Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001, 294: 605-609. 10.1126/science.1063916.View ArticlePubMedGoogle Scholar
  50. Nikolin VP, Popova NA, Sebeleva TE, Strunkin DN, Rogachev VA, Semenov DV, Bogachev SS, Yakubov LA, Shurdov MA: Effect of exogenous DNA injection on leukopoietic repair and antitumor action of cyclophosphamide. Vopr Onkol. 2006, 52: 336-340. In RussianPubMedGoogle Scholar
  51. Chabner B, Longo DL: Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, Lippincott Willians & Wilkins. 2006Google Scholar
  52. Mayer RJ: Targeted therapy for advanced colorectal cancer--more is not always better. N Engl J Med. 2009, 360: 623-625. 10.1056/NEJMe0809343.View ArticlePubMedGoogle Scholar
  53. Obeid M: ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J Immunol. 2008, 181: 2533-2543.View ArticlePubMedGoogle Scholar
  54. Khochenkov DM: Biology of dendritic cells. Biological membranes. 2008, 25: 403-419. In RussianGoogle Scholar
  55. Lutsiak ME, Tagaya Y, Adams AJ, Schlom J, Sabzevari H: Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol. 2008, 180: 5871-5881.PubMed CentralView ArticlePubMedGoogle Scholar
  56. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 2005, 23: 8950-8958. 10.1200/JCO.2005.12.147.View ArticlePubMedGoogle Scholar
  57. Pratesi G, Petrangolini G, Tortoreto M, Addis A, Belluco S, Rossini A, Selleri S, Rumio C, Menard S, Balsari A: Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res. 2005, 65: 6388-6393. 10.1158/0008-5472.CAN-05-0602.View ArticlePubMedGoogle Scholar
  58. Bopp T, Radsak M, Schmitt E, Schild H: New strategies for the manipulation of adaptive immune responses. Cancer Immunol Immunother. 2010, 59: 1443-1448. 10.1007/s00262-010-0851-z.View ArticlePubMedGoogle Scholar
  59. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004, 34: 336-344. 10.1002/eji.200324181.View ArticlePubMedGoogle Scholar
  60. Nikolin VP, Popova NA, Sebeleva TE, Strunkin DN, Rogachev VA, Semenov DV, Bogachev SS, Yakubov LA, Shurdov MA: Effect of exogenous DNA on the growth of transplantable tumors. Vopr Onkol. 2006, 52: 66-69. In RussianPubMedGoogle Scholar


© Alyamkina et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.